Challenging Clinical Decisions in Cancer Immunotherapy: First-Line Treatment of Advanced Non-small Cell Lung Cancer
Released On
August 11, 2023
Expires On
August 11, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Geriatric Medicine, Hematology-Oncology, Pharmacy, Primary Care, Pulmonology
Topic(s)
Lung Cancer, Oncology
This activity is provided by Med Learning Group.
This activity is co-provided by AMEDCO
Nursing learners, view this Learner Notification prior to starting this activity
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 ANCC Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of medical oncologists, oncology nurses, pharmacists, nurse practitioners and other members of the multidisciplinary team to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC.
Program Overview
The program is focused on providing an optimal learning environment that encourages improved knowledge and competence through short-form, high-impact visual learning. This program, led by a faculty expert, will inform clinicians of the the latest mechanistic data with single-agent and combination therapies for non-small cell lung cancer (NSCLC), including the mechanistic rationale for early-line combination therapy as a treatment option in advanced NSCLC. Clinical practice guidelines, including best practices for managing the safety of available therapies, will be integrated throughout the program. Clinicians will be exposed to current perspectives on first-line therapeutic options informing the use of immunotherapy in advanced NSCLC.
Educational Objectives
Upon the completion of this program, attendees should be able to:
- Evaluate recent first-line, mono-immunotherapy clinical trials data in the treatment of patients with advanced NSCLC without targetable mutations
- Discuss the first-line, immunotherapy combination regimen clinical data in the management of patients with advanced NSCLC
- Review the use of clinical practice guidelines in the management of patients with advanced NSCLC and no targetable mutations
Faculty
Debora S. Bruno MD, MS
Program Chair
Assistant Professor of Medicine
Medical Director, University Hospitals Dahms Clinical Research Unit
University Hospitals Cleveland Medical Center Case Comprehensive Cancer Center
Case Western Reserve University School of Medicine
Cleveland, OH
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation Statement
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™ Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationship(s)
- Debora S. Bruno, MD
- Consulting Fees: Amgen, Bristol Meyers Squibb, Novartis, Eli Lilly, Daiichi-Sankyo, AstraZeneca, Mirati Therapeutics
- Contracted Research: Bristol Meyers Squibb, Dragonfly Therapeutics, Mirati Therapeutics, Daiichi-Sankyo, AstraZeneca, Genetech, Seagen
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Michael Page, Medical Director for Med Learning Group, discloses an ownership stake in Advantific, LLC.
Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
Amanda Jenkins, Program Manager for Med Learning Group has nothing to disclose.
Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
Method of Participation
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: https://www.medlearninggroup.com/privacy-policy/
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Content - Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
